Posted on 02/02/2010 in Pharmaceutical Company Restructures Cephalon this week announced its plans to acquire the privately held Swiss firm Mepha AG, a deal which also includes the organisation's subsidiaries.
Mepha, which specialises in innovative dosage formulations and deals in both generic and branded generic products, will be bought for 622.5 million Swiss francs (369.7 million pounds).
The transaction, which is set to conclude within the next ten to 12 weeks, will serve to diversify Cephalon's business mix and will double the size of its international operations.
Additionally, it provides an existing platform from which to launch new products in emerging markets.
Frank Baldino, chairman and chief executive officer of Cephalon, said: "The addition of Mepha will transform our international business overnight, expanding our ability to serve global markets and reach patients in new territories for the first time."
Earlier this week, Cephalon revealed that it has promoted three of its executives - Kevin Buchi, Wilco Groenhuysen and Alain Aragues. Other news stories from 02/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
